Statements (29)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
|
gptkbp:approvalYear |
2014
|
gptkbp:approvedBy |
gptkb:FDA
|
gptkbp:ATCCode |
N05CM17
|
gptkbp:contraindication |
narcolepsy
|
gptkbp:drugClass |
orexin receptor antagonist
|
gptkbp:eliminatedIn |
urine
feces |
gptkbp:form |
gptkb:tablet
|
gptkbp:genericName |
gptkb:suvorexant
|
gptkbp:halfLife |
about 12 hours
|
https://www.w3.org/2000/01/rdf-schema#label |
Belsomra
|
gptkbp:indication |
treatment of sleep onset and/or sleep maintenance insomnia
|
gptkbp:legalStatus |
Schedule IV (US)
|
gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
gptkbp:marketedAs |
gptkb:United_States
|
gptkbp:mechanismOfAction |
orexin receptor antagonist
|
gptkbp:metabolism |
gptkb:liver_(CYP3A)
|
gptkbp:pregnancyCategory |
C (US)
|
gptkbp:prescriptionStatus |
prescription only
|
gptkbp:routeOfAdministration |
oral
|
gptkbp:sideEffect |
headache
dry mouth somnolence abnormal dreams daytime drowsiness |
gptkbp:usedFor |
insomnia
|
gptkbp:bfsParent |
gptkb:MRK
|
gptkbp:bfsLayer |
5
|